Anavip is a snake antivenom used to treat envenomation by North American rattlesnakes, officially designated crotalidae immune F(ab')2 (equine) and manufactured by Rare Disease Therapeutics. It is a divalent fragment antigen-binding protein preparation, F(ab')2, derived from the blood plasma of horses immunized with venom from two snake species, Bothrops asper and Crotalus durissus, produced through pepsin digestion of the horse plasma followed by purification to a preparation of more than 85 percent F(ab')2. It is indicated for the management of envenomation from North American rattlesnakes and is a prescription-only medication in the United States.
Facts
Classification
Approval Status ATC ClassSourced to the subject's own account Route of Administration First Approved / Isolated Year Sources
1. Anavip (Wikipedia)
Lead: approval status
Anavip is the brand name of a snake antivenin indicated for the management of people with North American rattlesnake envenomation.
- Route of administration
View the Source2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code VQuote, First-level anatomical group codes, Code V
Various
View the Source 3. Drugs.com/FDA: Anavip Crotalidae Immune F(ab)2 (Equine) Approval
Approval historyQuote, Approval history
Anavip was FDA approved in 2015 for North American rattlesnake envenomation, not released for distribution until 2018
View the Source Wikidata: Anavip
Wikidata Q98523655, class allow-list match (w-wdresolver-0926)View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.